Esophageal Squamous Cell Carcinoma
4 competing products in clinical development for Esophageal Squamous Cell Carcinoma.
Pipeline by Phase
Phase 1/21
Phase 22
Phase 31
All Products (4)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl) | Daiichi Sankyo | Phase 3 | Recruiting | 47 |
| Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue Medication | Daiichi Sankyo | Phase 1/2 | Recruiting | 39 |
| Sintilimab + Nab paclitaxel + Cisplatin | CSPC Pharmaceutical Group Limited | Phase 2 | Completed | 35 |
| Nivolumab | Ono Pharmaceutical | Phase 2 | UNKNOWN | 31 |